Regarding
breast cancer treatment,
triple negative breast cancer (TNBC) is a difficult issue. Most TNBC patients die of
cancer metastasis. Thus, to develop a new regimen to attenuate TNBC metastatic potential is urgently needed.
MART-10 (19-nor-2α-(3-hydroxypropyl)-1α,25(OH)₂D₃), the newly-synthesized 1α,25(
OH)₂D₃ analog, has been shown to be much more potent in
cancer growth inhibition than 1α,25(
OH)₂D₃ and be active in vivo without inducing obvious side effect. In this study, we demonstrated that both 1α,25(
OH)₂D₃ and
MART-10 could effectively repress TNBC cells migration and invasion with
MART-10 more effective.
MART-10 and 1α,25(
OH)₂D₃ induced
cadherin switching (upregulation of
E-cadherin and downregulation of
N-cadherin) and downregulated
P-cadherin expression in MDA-MB-231 cells. The EMT(epithelial mesenchymal transition) process in MDA-MB-231 cells was repressed by
MART-10 through inhibiting Zeb1, Zeb2, Slug, and Twist expression. LCN2, one kind of
breast cancer metastasis stimulator, was also found for the first time to be repressed by 1α,25(
OH)₂D₃ and
MART-10 in
breast cancer cells.
Matrix metalloproteinase-9 (MMP-9) activity was also downregulated by
MART-10. Furthermore,
F-actin synthesis in MDA-MB-231 cells was attenuated as exposure to 1α,25(
OH)₂D₃ and
MART-10. Based on our result, we conclude that
MART-10 could effectively inhibit TNBC cells metastatic potential and deserves further investigation as a new regimen to treat TNBC.